Steve Harr, Sana Biotechnology CEO

Four years in, Sana gets first FDA go-ahead to bring can­cer treat­ment in­to the clin­ic

Sana Biotech­nol­o­gy is fi­nal­ly head­ed to the clin­ic.

Thurs­day af­ter­noon, the biotech an­nounced the FDA had cleared its ap­pli­ca­tion to start a clin­i­cal tri­al for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.